Optimizing Urology Denial Management with Klivira

Common Denial Triggers in Urology

Urology practices frequently encounter denials stemming from specific high-volume prior authorization categories. These include advanced prostate cancer therapeutics like oral androgen-receptor inhibitors and PSMA-targeted radiopharmaceuticals, BPH treatments such as UroLift, Rezum, and Aquablation, and overactive bladder medications. Imaging services like multiparametric prostate MRI and PSMA PET also frequently face scrutiny, often due to specific NCD/LCD constraints.

Automated Denial Intake and Categorization

Klivira ingests denial data from all channels, including X12 835 remittance advice for billed services, X12 277 claim status for pre-service PA denials, and payer portal status events. Our platform normalizes X12 CARC/RARC codes and payer-specific variations into a uniform reason set, ensuring accurate categorization of denials for urology-specific services, from step therapy for OAB medications to medical-necessity gaps for prostate cancer drugs.

Key Urology Denial Reasons Addressed by Klivira

• **Step Therapy:** For erectile dysfunction treatments and overactive bladder medications like mirabegron/Myrbetriq.
• **Medical-Necessity Gaps:** For advanced prostate cancer drugs lacking sufficient staging documentation (e.g., Gleason score, PSA, NCCN-compendium-supported indication).
• **NCD/LCD Constraints:** Specific CMS LCDs for PSMA imaging (Gallium-68 PSMA, Pylarify/F-18-DCFPyL) requiring biochemical recurrence or initial staging documentation.
• **Conservative-Therapy Duration Insufficient:** For BPH treatments (UroLift, Rezum, Aquablation) and sacral neuromodulation (InterStim), where prior medical therapy trial duration is a common requirement.
• **Non-Covered Services:** Especially for erectile dysfunction treatments, which many plans classify as non-covered.

Intelligent Appeal Packet Assembly for Urology Cases

For clinical-necessity denials in urology, Klivira automates the assembly of appeal packets. The platform pulls relevant clinical documentation from the EMR via FHIR, including updated lab/imaging results (e.g., new PSA levels, MRI reports), revised problem lists, and notes added since the original PA submission. This ensures appeals for prostate cancer treatments or BPH procedures are submitted with the strongest available supporting evidence, aligned with AUA Clinical Practice Guidelines and NCCN guidelines for urologic oncology.

Proactive Timely Filing and Status Tracking

Manual tracking of appeal status and timely-filing windows is a significant failure mode in urology denial management. Klivira enforces per-payer timely-filing windows with proactive deadline surfacing and tracks appeal status across all submission channels (payer portal API, fax fallback, Da Vinci PAS-conformant resubmission). This prevents lost-to-follow-up appeals and ensures that appeals for urgent prostate cancer care or time-sensitive procedures are processed within required timelines.

Feedback Loop for Upstream PA Optimization

Klivira's denial management module provides robust reporting and pattern detection, identifying recurring denial reasons by payer, service line, and provider within urology. This intelligence feeds back into the upstream prior authorization submission process, allowing practices to refine documentation practices for specific drugs or procedures (e.g., ensuring all required BPH symptom scores or prostate cancer staging details are included) and ultimately reduce future denials.